Spark Therapeutics (NASDAQ:ONCE) PT Set at $105.00 by Cantor Fitzgerald

Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics (NASDAQ:ONCE) in a report issued on Tuesday, December 19th. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other research firms have also weighed in on ONCE. Goldman Sachs Group reiterated a buy rating and issued a $111.00 price objective on shares of Spark Therapeutics in a research note on Friday, October 6th. BMO Capital Markets set a $89.00 price objective on shares of Spark Therapeutics and gave the stock a buy rating in a research note on Tuesday, October 10th. Cowen reissued a buy rating and set a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Barclays increased their price target on shares of Spark Therapeutics from $104.00 to $107.00 and gave the stock an overweight rating in a report on Friday, October 13th. Finally, Stifel Nicolaus reissued a buy rating and set a $101.00 price target (up from $92.00) on shares of Spark Therapeutics in a report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. Spark Therapeutics has a consensus rating of Buy and an average price target of $76.03.

Shares of Spark Therapeutics (ONCE) traded up $1.21 during trading on Tuesday, reaching $54.07. 557,564 shares of the company’s stock were exchanged, compared to its average volume of 1,550,000. The firm has a market cap of $2,000.00 and a price-to-earnings ratio of -7.51. Spark Therapeutics has a twelve month low of $41.06 and a twelve month high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last released its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The business had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The firm’s revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($1.07) EPS. analysts expect that Spark Therapeutics will post -7.55 EPS for the current fiscal year.

In other news, insider Daniel Faga sold 7,500 shares of the stock in a transaction dated Tuesday, October 24th. The shares were sold at an average price of $80.96, for a total value of $607,200.00. Following the completion of the sale, the insider now directly owns 6,000 shares in the company, valued at $485,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Katherine A. High sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $71.32, for a total transaction of $356,600.00. Following the sale, the insider now owns 215,000 shares of the company’s stock, valued at $15,333,800. The disclosure for this sale can be found here. Insiders sold 62,309 shares of company stock valued at $4,621,085 over the last quarter. Company insiders own 7.30% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. increased its position in Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the last quarter. Vanguard Group Inc. increased its position in Spark Therapeutics by 5.3% during the second quarter. Vanguard Group Inc. now owns 1,924,463 shares of the biotechnology company’s stock worth $114,968,000 after purchasing an additional 96,803 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Spark Therapeutics by 46.4% during the third quarter. Janus Henderson Group PLC now owns 756,088 shares of the biotechnology company’s stock valued at $67,413,000 after acquiring an additional 239,723 shares during the last quarter. Finally, Orbimed Advisors LLC acquired a new stake in shares of Spark Therapeutics during the third quarter valued at about $38,340,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

WARNING: “Spark Therapeutics (NASDAQ:ONCE) PT Set at $105.00 by Cantor Fitzgerald” was published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://stocknewstimes.com/2018/01/11/spark-therapeutics-once-given-a-105-00-price-target-by-cantor-fitzgerald-analysts.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply